Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ATM095
MIFTS: 62

Autoimmune Disease

Categories: Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Autoimmune Disease

About this section

MalaCards integrated aliases for Autoimmune Disease:

Name: Autoimmune Disease 56 12 29 17
Autoimmune Diseases 54 42 15 71
Autoimmune Hypersensitivity Disease 12 15
Hypersensitivity Reaction Type Ii Disease 12
Type Ii Hypersensitivity Reaction Disease 17

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant gene epistatic to other secondary genes conferring specificity to the autoimmune phenotype


HPO:

31
autoimmune disease:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:417
OMIM 56 109100
ICD9CM 34 720
MedGen 41 C0004364
SNOMED-CT via HPO 68 263681008
UMLS 71 C0003089 C0004364
Sources

Summaries for Autoimmune Disease

About this section
MedlinePlus : 42 Your body's immune system protects you from disease and infection. But if you have an autoimmune disease, your immune system attacks healthy cells in your body by mistake. Autoimmune diseases can affect many parts of the body. No one is sure what causes autoimmune diseases. They do tend to run in families. Women - particularly African-American, Hispanic-American, and Native-American women - have a higher risk for some autoimmune diseases. There are more than 80 types of autoimmune diseases, and some have similar symptoms. This makes it hard for your health care provider to know if you really have one of these diseases, and if so, which one. Getting a diagnosis can be frustrating and stressful. Often, the first symptoms are fatigue, muscle aches and a low fever. The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling. The diseases may also have flare-ups, when they get worse, and remissions, when symptoms get better or disappear. Treatment depends on the disease, but in most cases one important goal is to reduce inflammation. Sometimes doctors prescribe corticosteroids or other drugs that reduce your immune response.

MalaCards based summary : Autoimmune Disease, also known as autoimmune diseases, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and autoimmune disease of peripheral nervous system. An important gene associated with Autoimmune Disease is GAS5 (Growth Arrest Specific 5), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Azithromycin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and thyroid, and related phenotypes are autoimmune antibody positivity and hematopoietic system

Disease Ontology : 12 An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.

Wikipedia : 74 An autoimmune disease is a condition arising from an abnormal immune response to a normal body part.... more...

More information from OMIM: 109100
Sources

Related Diseases for Autoimmune Disease

About this section

Diseases related to Autoimmune Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1463)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 35.5 PTPN22 NLRP1 CTLA4 AIRE
2 autoimmune disease of peripheral nervous system 35.0 TNF IL6 IL17A IL10
3 autoimmune disease of skin and connective tissue 35.0 TNF PTPN22 NLRP1 IL6 IL17A IL10
4 autoimmune disease of gastrointestinal tract 35.0 TNF PTPN22 IL6 IL17A IL10 IFNG
5 autoimmune disease of endocrine system 35.0 TNF PTPN22 IL6 IL17A IL10 IFNG
6 autoimmune disease of musculoskeletal system 34.9 TNF PTPN22 IL6 IL17A IL10 IFNG
7 systemic autoimmune disease 34.9 IL6 IL17A AIRE
8 autoimmune disease of central nervous system 34.9 TNF IL6 IL17A IL10 IFNG CTLA4
9 autoimmune disease of eyes, ear, nose and throat 34.8 TNF IL6 IL17A IL10 CTLA4
10 autoimmune disease of blood 34.8 TNF IL6 IL10 CTLA4
11 autoimmune disease of exocrine system 34.7 TNF IL6 IL17A IL10
12 systemic lupus erythematosus 34.4 TNF STAT3 PTPN22 NLRP1 IL6 IL17A
13 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 34.2 PTPN22 IL17A IL10 IFNG CTLA4 AIRE
14 hashimoto thyroiditis 34.2 TNF PTPN22 IL6 IL17A IL10 IFNG
15 rheumatoid arthritis 34.1 TNF SIAE PTPN22 NLRP1 IL6 IL17A
16 celiac disease 1 34.1 TNF PTPN22 IL6 IL17A IL10 IFNG
17 primary biliary cirrhosis 34.0 TNF PTPN22 IL6 IL17A IL10 IFNG
18 multiple sclerosis 34.0 TNF STAT3 PTPN22 IL6 IL17A IL10
19 myasthenia gravis 33.9 TNF PTPN22 IL10 IFNG CTLA4 AIRE
20 graves' disease 33.9 PTPN22 IFNG HLA-A CTLA4 AIRE
21 lupus erythematosus 33.9 TNF PTPN22 NLRP1 IL10 IFNG CTLA4
22 autoimmune hepatitis 33.8 TNF IL6 IL10 HLA-A CTLA4 AIRE
23 mixed connective tissue disease 33.8 TNF IL6 IL10 IFNG
24 diabetes mellitus, type i 33.8 TNF PTPN22 IL6 IL17A IL10 IFNG
25 diabetes mellitus 33.8 TNF STAT3 PTPN22 IL6 IL17A IL10
26 psoriasis 33.8 TNF STAT3 PTPN22 IL6 IL17A IL10
27 alopecia areata 33.8 TNF PTPN22 IL6 IL17A IL10 IFNG
28 vogt-koyanagi-harada disease 33.7 PTPN22 NLRP1 IL17A IL10 IFNG HLA-A
29 aplastic anemia 33.7 TNF STAT3 PTPN22 IL6 IL10 IFNG
30 common variable immunodeficiency 33.7 ZAP70 TNF STAT3 IL6 IL10 IFNG
31 interstitial lung disease 33.7 TNF IL6 IL17A IL10 IFNG
32 behcet syndrome 33.6 TNF PTPN22 IL6 IL17A IL10 IFNG
33 juvenile rheumatoid arthritis 33.6 TNF IL6 IL10 IFNG CTLA4
34 immune deficiency disease 33.6 ZAP70 TNF IL6 IL10 IFNG HLA-A
35 autoimmune gastritis 33.5 TNF IL6 IL10 IFNG AIRE
36 cutaneous lupus erythematosus 33.5 TNF IL6 IL17A IL10 IFNG CTLA4
37 exanthem 33.5 TNF IL6 IL10 IFNG CTLA4
38 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 33.5 STAT3 IL17A IL10 CTLA4 AIRE
39 autoimmune pancreatitis 33.5 TNF IL17A IL10 ENO1 CTLA4
40 myositis 33.4 TNF IL6 IL17A IFNG
41 autoimmune uveitis 33.4 TNF IL17A IL10 IFNG
42 granulomatosis with polyangiitis 33.4 TNF PTPN22 IL17A CTLA4
43 reactive arthritis 33.4 TNF IL6 IL17A IL10 IFNG
44 microscopic polyangiitis 33.4 TNF CTLA4
45 chronic inflammatory demyelinating polyradiculoneuropathy 33.3 IL17A IL10 IFNG
46 autoimmune polyendocrine syndrome 33.2 IL17A IL10 AIRE
47 optic neuritis 33.2 TNF IL6 IL10
48 autoimmune myocarditis 33.2 TNF IFNG
49 immune system disease 32.9 TNF IL6 IL17A IL10 CTLA4
50 melioidosis 32.9 TNF IL6 IL10 IFNG

Graphical network of the top 20 diseases related to Autoimmune Disease:



Diseases related to Autoimmune Disease
Sources

Symptoms & Phenotypes for Autoimmune Disease

About this section

Human phenotypes related to Autoimmune Disease:

31
# Description HPO Frequency HPO Source Accession
1 autoimmune antibody positivity 31 HP:0030057

Symptoms via clinical synopsis from OMIM:

56
Immunology:
autoimmune disease

Lab:
high titer autoantibody

Clinical features from OMIM:

109100

MGI Mouse Phenotypes related to Autoimmune Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 AIRE CTLA4 HLA-A IFNG IL10 IL17A
2 endocrine/exocrine gland MP:0005379 10.18 AIRE CTLA4 HLA-A IFNG IL10 IL17A
3 immune system MP:0005387 10.17 AIRE CTLA4 HLA-A IFNG IL10 IL17A
4 digestive/alimentary MP:0005381 10.13 AIRE CTLA4 IFNG IL10 IL17A IL6
5 integument MP:0010771 9.91 CTLA4 IFNG IL10 IL17A IL6 ITCH
6 liver/biliary system MP:0005370 9.81 AIRE CTLA4 IFNG IL10 IL6 ITCH
7 no phenotypic analysis MP:0003012 9.5 AIRE HLA-A IFNG IL10 IL17A SIAE
8 respiratory system MP:0005388 9.36 AIRE CTLA4 IFNG IL10 IL17A IL6
Sources

Drugs & Therapeutics for Autoimmune Disease

About this section

Drugs for Autoimmune Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 608)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043 55185
2
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
9
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
10
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
11
Insulin aspart Approved Phase 4 116094-23-6 16132418
12
Insulin glargine Approved Phase 4 160337-95-1
13
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
14
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
15
Halofantrine Approved Phase 4 69756-53-2 37393
16 Strawberry Approved Phase 4
17 Orange Approved Phase 4
18 Artichoke Approved Phase 4
19
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
20
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
21
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
22
Adalimumab Approved Phase 4 331731-18-1 16219006
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
25
Abatacept Approved Phase 4 332348-12-6 10237
26
Infliximab Approved Phase 4 170277-31-3
27
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
28
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
29
belimumab Approved Phase 4 356547-88-1 10451420 5957
30
Tofacitinib Approved, Investigational Phase 4 477600-75-2
31
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
32
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
33
Hydroxychloroquine Approved Phase 4 118-42-3 3652
34
Acetaminophen Approved Phase 4 103-90-2 1983
35
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
36
Povidone Approved Phase 4 9003-39-8
37
Vancomycin Approved Phase 4 1404-90-6 14969 441141
38
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
39
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
40
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
42
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
43
Adefovir Investigational Phase 4 106941-25-7
44 Tocotrienol Investigational Phase 4 6829-55-6
45 Rosuvastatin Calcium Phase 4 147098-20-2
46 Angiotensin Receptor Antagonists Phase 4
47 Angiotensin II Type 1 Receptor Blockers Phase 4
48 Angiotensinogen Phase 4
49 Giapreza Phase 4
50 Vitamins Phase 4

Interventional clinical trials:

(show top 50) (show all 1457)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
2 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Unknown status NCT02419378 Phase 4 Alemtuzumab
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
5 A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
6 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Unknown status NCT03092544 Phase 4 dimethyl fumarate
7 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
8 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
9 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03540472 Phase 4 tacrolimus
10 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03364764 Phase 4 Sirolimus
11 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
12 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
13 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
14 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
15 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
16 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
17 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
18 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
19 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
20 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
21 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
22 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
23 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTAâ„¢ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
24 Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Multi- Systemic Effect of Vitamin D Supplementation on Young Men With Vitamin D Deficiency Completed NCT01016184 Phase 4
25 Placebo Controlled Study to Assess the Effects of Vitamin D Supplementation on Parameters of the Immune, Endocrine and Metabolic System in Healthy Women and Men. Completed NCT01248442 Phase 4 Cholecalciferol;Placebo
26 Placebo Controlled Pilot Study on Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes on Immunological, Endocrine and Metabolic Parameters: Step 2 in the Austrian Diabetes Prevention Programme Completed NCT01390480 Phase 4 Cholecalciferol
27 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
28 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
29 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
30 Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria Completed NCT01295879 Phase 4 Ergocalciferol
31 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
32 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
33 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
34 Comparison of Two Standard High-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents: Associations of Vitamin D Repletion With Changes in Markers of Musculoskeletal, Cardiometabolic, and Immune Function Completed NCT01784029 Phase 4 Vitamin D3
35 A Phase IV, Open Label Study Introducing a Single IV Treatment With Abatacept in Patients With Rheumatoid Arthritis Currently Receiving Weekly Injections of SC Abatacept to Simulate a Holiday or Patient Vacation Completed NCT01846975 Phase 4 IV Abatacept
36 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
37 A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis Completed NCT00896168 Phase 4 Infliximab;Methotrexate
38 EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS Completed NCT01872455 Phase 4
39 SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) Completed NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
40 Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion Completed NCT00454428 Phase 4
41 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
42 Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial. Completed NCT03368430 Phase 4 Placebo
43 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
44 Patient-Reported AutoImmunity Secondary to Cancer immunothErapy Recruiting NCT03849131 Phase 4
45 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
46 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
47 Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial Recruiting NCT04161339 Phase 4 Hydroxychloroquine;Placebo oral tablet
48 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis Recruiting NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
49 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study Recruiting NCT03214731 Phase 4 Artesunate
50 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Recruiting NCT02973295 Phase 4 Silymarin

Search NIH Clinical Center for Autoimmune Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Prednisone
PREDNISONE PWDR
Sources

Genetic Tests for Autoimmune Disease

About this section

Genetic tests related to Autoimmune Disease:

# Genetic test Affiliating Genes
1 Autoimmune Disease 29
Sources

Anatomical Context for Autoimmune Disease

About this section

MalaCards organs/tissues related to Autoimmune Disease:

40
T Cells, B Cells, Thyroid, Bone, Liver, Skin, Neutrophil
Sources

Publications for Autoimmune Disease

About this section

Articles related to Autoimmune Disease:

(show top 50) (show all 54518)
# Title Authors PMID Year
1
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. 61 56
9707586 1998
2
Familial polyarteritis nodosa: a serologic and immunogenetic analysis. 61 56
2568486 1989
3
Classification of experimental data for genetic analysis in autoimmune disease. 61 56
3337106 1988
4
Evidence that autoimmunity in man is a Mendelian dominant trait. 56 61
3098096 1986
5
Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. 56 61
6437309 1984
6
Genetic factors predisposing to autoimmune diseases. Autoimmune hemolytic anemia, chronic thrombocytopenic purpura, and systemic lupus erythematosus. 56 61
6756137 1982
7
H gene theory of inherited autoimmune disease. 56 61
6101848 1980
8
SARS-CoV-2 infection among patients with systemic autoimmune diseases. 42 61
32376395 2020
9
Lymphoma in the setting of autoimmune diseases: A review of association and mechanisms. 61 42
32353704 2020
10
Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. 56
10599734 1999
11
Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. 56
10573514 1999
12
Familial polyarteritis nodosa. 56
7914412 1994
13
On genetic components in autoimmunity: a critical review based on evolutionarily oriented rationality. 56
1483686 1992
14
Evidence that autoimmunity in man is a Mendelian dominant trait. 56
3337107 1988
15
Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. 56
3484749 1986
16
[Familial autoimmune pathology comprising 2 cases of primary biliary cirrhosis]. 56
6578990 1983
17
Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. 56
7195175 1981
18
The genetic lesions of autoimmunity. 56
6769621 1980
19
Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis. 56
5660845 1968
20
MYASTHENIA GRAVIS AND HYPERTHYROIDISM IN TWO SISTERS. 56
14158527 1964
21
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. 42
32376399 2020
22
A biochemical and genetic study on all non-synonymous single nucleotide polymorphisms of the gene encoding human deoxyribonuclease I potentially relevant to autoimmunity. 61 54
20417303 2010
23
Functional signaling of membrane-bound TL1A induces IFN-gamma expression. 54 61
20403353 2010
24
Retinoic acid-inducible gene-I (RIG-I) is induced by IFN-{gamma} in human mesangial cells in culture: possible involvement of RIG-I in the inflammation in lupus nephritis. 61 54
20167631 2010
25
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. 61 54
20459090 2010
26
Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases. 54 61
20166877 2010
27
IL-9: basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity. 61 54
20020328 2010
28
Evaluation of 6 candidate genes on chromosome 11q23 for coeliac disease susceptibility: a case control study. 54 61
20478055 2010
29
Genetic risk factors in lupus nephritis and IgA nephropathy--no support of an overlap. 61 54
20479942 2010
30
STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn's disease in the Spanish population: a replication study. 61 54
20153791 2010
31
The +49A>G CTLA-4 polymorphism is associated with rheumatoid arthritis in Mexican population. 61 54
20138855 2010
32
Interleukin-17 and its expanding biological functions. 61 54
20383173 2010
33
Expression of IFNalpha-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. 61 54
20015465 2010
34
The ROQUIN family of proteins localizes to stress granules via the ROQ domain and binds target mRNAs. 54 61
20412057 2010
35
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. 61 54
20383174 2010
36
Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. 54 61
20434372 2010
37
High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. 61 54
19963070 2010
38
HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves' disease. 61 54
20300120 2010
39
Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. 54 61
19863576 2010
40
ST2: a novel biomarker for heart failure. 54 61
20465500 2010
41
American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 2. 21-25 March 2010, San Francisco, CA, USA. 61 54
20432181 2010
42
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. 61 54
19945799 2010
43
Study on VNTR polymorphism of gene IL-1RA in 19 Chinese populations. 54 61
20002810 2010
44
Comprehensive sequence analysis of the human IL23A gene defines new variation content and high rate of evolutionary conservation. 61 54
20154336 2010
45
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 54 61
20454450 2010
46
Immune responses to Epstein-Barr virus in individuals with systemic and organ specific autoimmune disorders. 61 54
20404456 2010
47
Immunoglobulin heavy chain variable region genes contribute to the induction of thyroid-stimulating antibodies in recombinant inbred mice. 54 61
20407472 2010
48
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis. 61 54
20415859 2010
49
Association of signal transducer and activator of transcription 4 genetic variants with extra-intestinal manifestations in inflammatory bowel disease. 54 61
20176035 2010
50
The interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication for autoimmunity. 54 61
20187706 2010
Sources

Variations for Autoimmune Disease

About this section

Copy number variations for Autoimmune Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21625 1 159859611 159867782 Copy number FCGR3B Autoimmune disease
2 21792 1 161592989 161601158 Copy number FCGR3B Autoimmune disease
3 21796 1 161592989 161601158 Deletion FCGR3B Autoimmune disease
4 208909 6 211050653 211252076 Copy number CYP21B Autoimmune disease
5 210508 6 30400000 36600000 Copy number CYP21A Autoimmune disease
6 210509 6 30400000 36600000 Copy number TNXA Autoimmune disease
7 211044 6 3197570 32111174 Copy number C4A Autoimmune disease
8 211046 6 3197570 32111174 Copy number C4B Autoimmune disease
Sources

Expression for Autoimmune Disease

About this section
Search GEO for disease gene expression data for Autoimmune Disease.
Sources

Pathways for Autoimmune Disease

About this section

Pathways related to Autoimmune Disease according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14 ZAP70 TNF STAT3 PTPN22 NLRP1 ITCH
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 TNF STAT3 IL6 IL17A IL10 IFNG
3
Allograft rejection 1 36
Show member pathways
 12.81 TNF IL6 IL17A IL10 IFNG HLA-A
4
Measles 36
Show member pathways
 12.78 TNF STAT3 IL6 IFNG HLA-A
5
Immune response IL-23 signaling pathway 22
Show member pathways
 12.55 TNF STAT3 IL6 IL17A IL10 IFNG
6
Th17 cell differentiation 36
Show member pathways
 12.34 ZAP70 TNF STAT3 IL6 IL17A IL10
7
IL-17 Family Signaling Pathways 64
Show member pathways
 12.32 TNF STAT3 IL6 IL17A IFNG
8
Toxoplasmosis 36
Show member pathways
 12.23 TNF STAT3 IL10 IFNG
9
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.23 TNF IL6 IL17A IL10 IFNG HLA-A
10
Tuberculosis 36
12.2 TNF IL6 IL10 IFNG
11
Colorectal Cancer Metastasis 63
12.16 TNF STAT3 IL6 IFNG
12
T cell receptor signaling pathway 36
Show member pathways
 12.1 ZAP70 TNF STAT3 IL6 IL17A IL10
13
Yersinia infection 36
12 ZAP70 TNF IL6 IL10
14
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.98 TNF IL6 IL10 IFNG
15
HIF-1 signaling pathway 36
11.94 STAT3 IL6 IFNG ENO1
16
Interleukin-4 and 13 signaling 65
11.93 TNF STAT3 IL6 IL17A IL10
17
Amoebiasis 36
11.91 TNF IL6 IL10 IFNG
18
Th17 Differentiation 64
Show member pathways
 11.85 STAT3 IL6 IL17A IFNG
19
NF-kappaB Signaling 4
11.84 ZAP70 TNF STAT3 PTPN22 NLRP1 ITCH
20
Innate Lymphoid Cells Differentiation 64
11.78 TNF IL17A IL10 IFNG
21
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.75 TNF ITCH IFNG CTLA4
22
Pertussis 36
11.73 TNF IL6 IL10
23
Dendritic Cells Developmental Lineage Pathway 64
11.73 TNF IL6 IL10 IFNG
24
Rheumatoid arthritis 36
11.73 TNF IL6 IL17A IFNG CTLA4
25
CTLA4 Signaling 63
11.69 ZAP70 PTPN22 CTLA4
26
IL27-mediated signaling events 1
Show member pathways
 11.66 TNF STAT3 IL6 IL17A IL10 IFNG
27
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 TNF IL6 IFNG
28
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.62 TNF IFNG HLA-A
29
TGF-beta Receptor Signaling (WikiPathways) 1
11.59 TNF STAT3 IFNG
30
Photodynamic therapy-induced AP-1 survival signaling. 1
11.53 TNF IL6 IFNG
31
Malaria 36
11.51 TNF IL6 IL10